Chinook Therapeutics

$16.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.17 (-1.00%) As of 4:28 PM UTC today

Why Robinhood?

You can buy or sell KDNY and other stocks, options, and ETFs commission-free!

About KDNY

Chinook Therapeutics, Inc. Common Stock, also called Chinook Therapeutics, is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. The listed name for KDNY is Chinook Therapeutics, Inc. Common Stock.

CEO
Eric L. Dobmeier
Employees
96
Headquarters
Seattle, Washington
Founded
2000
Market Cap
704.59M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
121.57K
High Today
$17.26
Low Today
$16.54
Open Price
$17.01
Volume
104.42K
52 Week High
$21.68
52 Week Low
$9.35

KDNY Earnings

-$0.29
-$0.19
-$0.10
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected May 3, Pre-Market

You May Also Like

HTIA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure